In-Depth Study on Gastric Cancer - Pipeline Review, H2 2016

Gastric Cancer - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Gastric Cancer (Oncology) pipeline landscape.

Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. Risk factors include smoking, pernicious anemia, stomach polyps, infection with helicobacter pylori and family history of stomach cancer. Treatment includes surgery, chemotherapy and radiation therapy.

To access full report with TOC, please visit Gastric Cancer - Pipeline Review, H2 2016

Report Highlights

This report provides comprehensive information on the therapeutics under development for Gastric Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastric Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 15, 68, 68, 7, 65, 6 and 2 respectively for Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 5, 3, 7 and 1 molecules, respectively for Gastric Cancer.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Gastric Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide evaluates Gastric Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gastric Cancer (Oncology).
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

3SBio Inc. AB Science SA AbbVie Inc AbGenomics International, Inc. ADC Therapeutics Sarl Advaxis, Inc. Advenchen Laboratories, LLC Agenus, Inc. Almac Discovery Limited Alteogen Inc. Ambrx, Inc. Amgen Inc. arGEN-X BV Asana BioSciences, LLC Aslan Pharmaceuticals Pte Ltd Astellas Pharma Inc. AstraZeneca Plc Atara Biotherapeutics, Inc. Athenex, Inc. Azaya Therapeutics, Inc. Basilea Pharmaceutica Ltd. Bayer AG BeiGene, Ltd. Betta Pharmaceuticals Co. Ltd. Bionovis SA Boehringer Ingelheim GmbH Boston Biomedical, Inc. Bristol-Myers Squibb Company Calithera Biosciences, Inc. Cancer Prevention Pharmaceuticals, Inc. Celgene Corporation Celldex Therapeutics, Inc. Cellectar Biosciences, Inc. Celltrion, Inc. Celon Pharma Sp. z o.o. Cerulean Pharma, Inc. Chipscreen Biosciences Ltd Curaxys, S.L. DAE HWA Pharmaceutical Co., Ltd. Daiichi Sankyo Company, Limited Debiopharm International SA Deciphera Pharmaceuticals, LLC Dong-A Socio Holdings Co. Ltd. Dr. Reddy's Laboratories Limited Eddingpharm EirGenix Inc. Eli Lilly and Company Esperance Pharmaceuticals, Inc. F. Hoffmann-La Roche Ltd. Five Prime Therapeutics, Inc. Frost Biologic, Inc. Galena Biopharma, Inc. Genelux Corporation Genentech, Inc. Gilead Sciences, Inc. GlaxoSmithKline Plc GlycoNex Inc. Glycotope GmbH Green Cross Corporation Halozyme Therapeutics, Inc. Hanmi Pharmaceuticals, Co. Ltd. Horizon Pharma Plc Hutchison MediPharma Limited Ignyta, Inc. Immunomedics, Inc. Imugene Limited Incyte Corporation Inovio Pharmaceuticals, Inc. INSYS Therapeutics, Inc. Intezyne Technologies, Inc. Jiangsu Hengrui Medicine Co., Ltd. Jiangsu Kanion Pharmaceutical Co., Ltd. Johnson & Johnson KaloBios Pharmaceuticals, Inc. Karyopharm Therapeutics, Inc. Kolltan Pharmaceuticals, Inc. Kuhnil Pharmaceutical Co., Ltd. Kyowa Hakko Kirin Co., Ltd. LegoChem Biosciences, Inc Les Laboratoires Servier SAS MacroGenics, Inc. MaxiVAX SA Mebiopharm Co., Ltd. MedImmune, LLC Medivation, Inc. Merck & Co., Inc. Merck KGaA Merrimack Pharmaceuticals, Inc. Mersana Therapeutics, Inc. Merus NV Millennium Pharmaceuticals Inc Mirna Therapeutics, Inc. Molecular Targeting Technologies, Inc. MolMed S.p.A. NanoCarrier Co., Ltd. NeuClone Pty Ltd Novartis AG OBI Pharma, Inc. Omnitura Therapeutics Inc. Oncobiologics, Inc. Oncolys BioPharma Inc Oncolytics Biotech Inc. OncoMed Pharmaceuticals, Inc. OncoTherapy Science, Inc. Ono Pharmaceutical Co., Ltd. Opsona Therapeutics Limited Panacea Biotec Limited Patrys Limited Pfizer Inc. Pharma Mar, S.A. Puma Biotechnology, Inc. Rexahn Pharmaceuticals, Inc. Rgenix, Inc. Rhizen Pharmaceuticals S.A. Richter Gedeon Nyrt. Samumed LLC Sanofi Sequella, Inc. Shanghai Henlius Biotech Co., Ltd. Shionogi & Co., Ltd. Simcere Pharmaceutical Group Sorrento Therapeutics, Inc. Spectrum Pharmaceuticals, Inc. Supratek Pharma Inc. SynCore Biotechnology Co., Ltd. Synovo GmbH Synthon Holdings BV Taiho Pharmaceutical Co., Ltd. Taiwan Liposome Company, Ltd. Takeda Pharmaceutical Company Limited Takis S.r.l. Tara Immuno-Oncology Therapeutics LLC Tessa Therapeutics Pte Ltd Transgene SA United BioPharma, Inc. Vaxon Biotech XuanZhu Pharma Co., Ltd. Zymeworks Inc.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###